CHIME’s biologic products are designed to introduce specific epitopes from childhood vaccines into tumors after administration with a delivery system (e.g., viral vector) to rapidly stimulate and expand existing effector memory T cells that patrol the body to destroy such ‘infected’ cells (Fact Sheet, JLABS, SEP 22, 2017, View Source [SID1234520598]). The recall and redirection of pre-existing memory T-cells against tumor cells should present a number of advantages compared to other immunotherapies: it does not require the discovery of cancer antigens and it does not need to break tolerance since it is based upon a non-self approach; it also does not require ex vivo manipulation of cells and it can be administered directly to patients as a biologic. CHIME’s product should be applicable to all types of tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CHIME’s unique approach does not require to modify or educate naive T cells but rather promotes the recruitment and activation of pre-existing vaccine-derived memory T cells to the cancerous tissue. The unique advantages of CHIME’s approach based on memory responses is expected to induce a strong and rapid direct tumor killing, decrease the tumor-mediated immune suppression, and drive the development of a systemic tumor-specific immunity through the release of tumor-associated antigens that are taken up by antigen presenting cells and presented to T cells to generate tumor-specific effector cells and tumor-specific immune memory.